Flexus Biosciences

Flexus Biosciences was a South San Francisco / San Carlos, California biotechnology company founded in 2013 to develop small-molecule cancer immunotherapies, most notably inhibitors of the IDO/TDO immunosuppressive pathway (lead IDO1 program F001287). Backed by Kleiner Perkins and The Column Group, it was acquired by Bristol-Myers Squibb in February 2015 for up to roughly $1.25 billion (about $800M upfront) to expand BMS's immuno-oncology pipeline. The company no longer operates independently; its domain redirects to the Bristol-Myers Squibb acquisition announcement. It publishes no public developer portal, documentation, or API, so this profile carries company identity only and no technical API artifacts.

Flexus Biosciences is profiled on the APIs.io network. Tagged areas include Company, Healthcare, Biotechnology, Pharmaceuticals, and Immuno-Oncology.

🌐 Visit website 📡 Source on GitHub

5.7/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyHealthcareBiotechnologyPharmaceuticalsImmuno-OncologyCancerDrug DiscoveryAcquired

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 5.7/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.0 / 20

Commercial Clarity 0.0 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/flexus-biosciences: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Source (apis.yml)

aid: flexus-biosciences
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/flexus-biosciences.png
name: Flexus Biosciences
description: Flexus Biosciences was a South San Francisco / San Carlos, California biotechnology company founded in 2013 to
  develop small-molecule cancer immunotherapies, most notably inhibitors of the IDO/TDO immunosuppressive pathway (lead IDO1
  program F001287). Backed by Kleiner Perkins and The Column Group, it was acquired by Bristol-Myers Squibb in February 2015
  for up to roughly $1.25 billion (about $800M upfront) to expand BMS's immuno-oncology pipeline. The company no longer operates
  independently; its domain redirects to the Bristol-Myers Squibb acquisition announcement. It publishes no public developer
  portal, documentation, or API, so this profile carries company identity only and no technical API artifacts.
url: https://raw.githubusercontent.com/api-evangelist/flexus-biosciences/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- kleiner-perkins
x-tier: stub
x-tier-reason: portfolio-lead
x-status: acquired
x-acquired-by: bristol-myers-squibb
x-acquired-date: 2015-02
x-acquisition-announcement: https://news.bms.com/press-release/rd-news/bristol-myers-squibb-expand-its-immuno-oncology-pipeline-agreement-acquire-fle/
x-no-api-surface: true
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Healthcare
- Biotechnology
- Pharmaceuticals
- Immuno-Oncology
- Cancer
- Drug Discovery
- Acquired
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence